Challenges in Heart Transplantation in the Era of COVID-19
2020; Lippincott Williams & Wilkins; Volume: 141; Issue: 25 Linguagem: Inglês
10.1161/circulationaha.120.047096
ISSN1524-4539
AutoresErsilia M. DeFilippis, Maryjane Farr, Michael M. Givertz,
Tópico(s)COVID-19 Clinical Research Studies
ResumoHomeCirculationVol. 141, No. 25Challenges in Heart Transplantation in the Era of COVID-19 Free AccessArticle CommentaryPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessArticle CommentaryPDF/EPUBChallenges in Heart Transplantation in the Era of COVID-19 Ersilia M. DeFilippis, Maryjane A. Farr and Michael M. Givertz Ersilia M. DeFilippisErsilia M. DeFilippis Division of Cardiology, Columbia University Irving Medical Center, New York (E.M.D., M.A.F.). , Maryjane A. FarrMaryjane A. Farr Division of Cardiology, Columbia University Irving Medical Center, New York (E.M.D., M.A.F.). and Michael M. GivertzMichael M. Givertz Michael M. Givertz, MD, Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. Email E-mail Address: [email protected] https://orcid.org/0000-0003-1012-7710 Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (M.M.G.). Originally published21 Apr 2020https://doi.org/10.1161/CIRCULATIONAHA.120.047096Circulation. 2020;141:2048–2051Other version(s) of this articleYou are viewing the most recent version of this article. Previous versions: April 21, 2020: Ahead of Print The cardiovascular community faces unprecedented challenges during the coronavirus disease 2019 (COVID-19) pandemic. For heart transplant (HT) clinicians, the global pandemic has unique implications for patients, including those on the waiting list and transplant recipients. These populations are at increased risk for both acquisition of COVID-19 infection and progression to severe disease given multiple healthcare contacts, underlying health conditions, and immunosuppression; targeted prevention and treatment strategies are needed.Past experience with previous coronavirus epidemics such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) demonstrated that transplant patients had similar presentations to the general population.1 Data are rapidly accumulating on the impact of COVID-19 within the transplant community. COVID-19 cases have already been reported in 2 HT recipients in China. Both patients survived, one with a mild form of illness allowing for treatment and recovery at home, the other with progressive respiratory failure requiring inpatient admission, intravenous immunoglobulin, and methylprednisolone.2 Mild-moderate presentations with uncomplicated courses have also been reported after kidney and liver transplant. Since these initial reports, a growing number of solid organ transplant recipients have been hospitalized for COVID-19, particularly in New York City. In-hospital disease transmission is increasing, with hospitals increasingly cohorting patients with COVID-19 in separate intensive care units and wards, irrespective of transplant status. Specific to HT recipients, manifestations of myocarditis—with high troponin levels, ECG changes, and new left ventricular dysfunction—may be mistaken for rejection. Yet endomyocardial biopsies are being restricted because of risks of exposure. The scope and scale of the current epidemic are unmatched, and online reports raise concerns about rapidly progressive disease leading to morbidity and mortality.3Important decisions have already arisen about actively listed patients. At any given time, a significant portion of patients are waiting in-hospital for HT. These patients are at higher risk for contracting the virus compared with others waiting at home. If they are subsequently infected with COVID-19, they are at risk for more severe infection (or coinfection) because of their underlying health conditions, and risk delisting. If possible, these patients should not be cared for by nurses who also have COVID-19–positive patients. However, as cases continue to rise, this may not be feasible. For all listed patients, no matter whether they are hospitalized or at home, transplant centers should highlight the wait list mortality risk–benefit ratio and provide institutional updates by direct telephone communication or a letter followed by a telephone communication.As the pandemic continues to evolve, a center's transplant volume may require staged reduction to meet intensive care unit bed, staffing, and medical equipment needs of the majority nontransplant population.4 Many centers in the United States, particularly in New York, have inactivated most of their HT waiting list, reserving active transplant status for only those patients with a presumed wait list mortality of 1 to 2 weeks, thus limiting transplant to patients in tiers 1 or 2 of the new heart allocation policy. Restrictions are also in effect for highly sensitized patients requiring intensive perioperative care and prolonged immunosuppression and with the need for frequent biopsy surveillance. It is uncertain whether women may be disproportionally affected in access to transplant, given their high sensitivity rates. For listed patients who are hospitalized without a strict contraindication to durable left ventricular assist device implantation, left ventricular assist device as a bridge to transplant may be a viable strategy to get at-risk patients home and out of the hospital, minimizing their exposure to COVID-19. Left ventricular assist device implants should not be performed in elective cases because of resource constraints and potential for nosocomial infection.These issues of feasibility and safety extend not only to recipients but also to organ donors, organ procurement organizations, and recovery teams. As COVID-19 continues to spread, we must be vigilant in choosing uninfected donors, recognizing that many may be asymptomatic carriers and that current testing has limitations. Chest computed tomography may also be necessary to exclude radiographic pneumonia. In discussing donor offers with listed patients, expanded consent should include the potential risks of a COVID-19–positive donor, despite procedures in place to mitigate risk. It is equally important to protect procurement teams, who are asked to perform time-sensitive, invasive procedures in unfamiliar facilities that may lack appropriate personal protective equipment or experienced operating room staff. Important organ procurement organization measures in the United States include expansion of the Uniform Donor Risk Assessment Interview, which now includes targeted questions on exposure to COVID-19. Mandatory COVID-19 testing for all donors is the goal, which is now occurring with increasing frequency in most regions of the United States. If donors test positive for COVID-19, their organs should not be used for transplant, although they could be considered for scientific purposes to better understand the effects of the virus on the myocardium. COVID-19–specific codes have been used to inform the United Network of Organ Sharing, the federally contracted organization that keeps track of all solid organ transplantation, of the circumstances under which an organ was not accepted.3For patients who require HT during this pandemic, rapid polymerase chain reaction testing to exclude community- or hospital-acquired COVID-19 infection is required, and extra precautions should be taken to mitigate the risk of postoperative exposure. This extends to visitors (many of whom are restricted at various hospitals across the country), nurses, respiratory therapists, and other intensive care unit staff. Negative pressure rooms in a COVID-19–free zone should be standard of care. Recipients should be retested before hospital discharge and receive focused education around disease prevention at home.The changing landscape also affects the post-HT ambulatory population. To reduce hospital volumes, most outpatient practices have shifted toward telemedicine. Virtual medicine minimizes in-person contact with the healthcare system, reducing patient risk of exposure. However, patients still must go to laboratories for serum drug levels of immunosuppressive agents. One question that arises is how we can or should monitor for rejection in stable outpatients if right heart catheterization and endomyocardial biopsy are deemed nonurgent. Perhaps institutions will shift to increased use of noninvasive monitoring with echocardiography, gene profiling (for acute cellular rejection), or donor-derived cell free DNA (for antibody-mediated rejection). What is considered "medically necessary" for these patients? What will be the implications of postponing some of this routine care on the rates of rejection or cardiac allograft vasculopathy in the longer term?Multidisciplinary HT teams must counsel patients and families on appropriate preventative measures. In 1 epidemiological study in China of 87 HT recipients, 97% adopted prevention and quarantine measures with a low rate of infection.5 We should recognize that given their immunosuppressed states, these patients may have both typical (respiratory) and atypical (gastrointestinal) COVID-19 illness. For HT patients admitted with COVID-19 infection, some have advocated for reduced immunosuppression and moderate-dose IV steroids.The role of novel therapy (eg, remdesivir, tocilizumab) should be tested in clinical trials before treatment algorithms are promulgated widely, with particular attention to drug–drug interactions and QT prolongation.Many questions remain, and the available knowledge on the virus and its impact on special populations is rapidly evolving (Table). As a community, we have a responsibility to share information in real time, gather more research, and provide guidance to other transplant providers, our multidisciplinary teams, and patients. Transparency with patients and other centers is key for the transplant community to come through this pandemic stronger.Table. Areas for Consideration During COVID-19 PandemicTransplant AreaRecommendations/ConsiderationsGaps in KnowledgeDonor offersObtain COVID-19–focused travel and social historyRisk factors for infectionRole of donor contact tracingExclude donors at increased risk of other disease transmission (eg, HIV, HBV, HCV)Exclude marginal donors (eg, LVH, mild LV dysfunction)Donor testingConfirm availability and rapid turn-around of PCR assayUniversal vs. targeted testingNeed for chest CT to exclude viral pneumoniaObtain at least 2 tests to increase sensitivity and specificityWindow period of infectionActively listed patientsEnsure COVID-19–free hospital locationSeparate consent for potential COVID-19–positive donorsNurses who treat patients with COVID-19 should not be assigned to patients awaiting transplantTemporary inactivation of stable outpatients (UNOS status 4–6)PCR assay to exclude hospital-acquired infectionLower threshold for implantation of LVAD as BTTTelephone or mail communication regarding expected delays and changes in institutional policiesNeed to reduce overall program transplant activityImmediate posttransplant managementAssign to negative pressure ventilation room with airborne isolationNeed to alter threshold for induction therapyNurses who treat patients with COVID-19 should not be assigned to posttransplant patientsLimit staff contact and outside visitorsAmbulatory posttransplant managementPatient/family hygiene including frequent hand-washing and social distancingThreshold for urgent, in-person visit vs. routine telemedicineEnsure that patients with symptoms concerning for rejection receive prompt testing and diagnosisNeed for self-quarantineImplications of delaying endomyocardial biopsies and noninvasive elective testingDelay elective testing, including echocardiography, RHC, and endomyocardial biopsyNovel methods for rejection surveillanceVaccine developmentLaboratory work at a local laboratory or using home services rather than at the hospital to minimize exposureTransplant patients with COVID-19 infectionConsider reduced-dose CNI and holding MMF/azathioprineRole of IL-6 depletion (eg, tocilizumab) for cytokine-release syndromeRule out coinfection (bacterial, fungal)Effectiveness of remdesivir in shortening time to recoveryMonitor time course of viremiaMonitoring for allograft dysfunction (cardiac biomarkers, point-of-care ultrasound)Monitor for drug-drug interactionsContinue statins (unless elevated LFTs, CK) and ACE inhibitors/ARBs (unless acute kidney injury or hypotension)ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor blocker; BTT, bridge-to-transplant; CK, creatine kinase; CNI, calcineurin inhibitor; COVID-19, coronavirus disease 2019; CT, computerized tomography; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IL-6, interleukin 6; LFT, liver function test; LV, left ventricular; LVAD, left ventricular assist device; LVH, left ventricular hypertrophy; MMF, mycophenolate mofetil; PCR, polymerase chain reaction; RHC, right heart catheterization; and UNOS, United Network of Organ Sharing.DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.https://www.ahajournals.org/journal/circMichael M. Givertz, MD, Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. Email mgivertz@bwh.harvard.eduReferences1. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, Jain SS, Burkhoff D, Kumaraiah D, Rabbani L, et al. COVID-19 and cardiovascular disease.Circulation. 2020; 141:1648–1655. doi: 10.1161/CIRCULATIONAHA.120.046941LinkGoogle Scholar2. Li F, Cai J, Dong N. First cases of COVID-19 in heart transplantation from China.J Heart Lung Transplant. March 17, 2020. doi: 10.1016/j.healun.2020.03.006. [Epub ahead of print].Google Scholar3. United Network for Organ Sharing. COVID-19 and solid organ transplant.https://unos.org/covid/. Accessed March 25, 2020.Google Scholar4. Kumar D, Manuel O, Natori Y, Egawa H, Grossi P, Han SH, Fernández-Ruiz M, Humar A. COVID-19: a global transplant perspective on successfully navigating a pandemic.Am J Transplant. March 23, 2020. doi: 10.1111/ajt.15876. [Epub ahead of print].CrossrefGoogle Scholar5. Ren ZL, Hu R, Wang ZW, Zhang M, Ruan YL, Wu ZY, Wu HB, Hu XP, Hu ZP, Ren W, et al. Epidemiologic and clinical characteristics of heart transplant recipients during the 2019 coronavirus outbreak in Wuhan, China: a descriptive survey report.J Heart Lung Transplant. 2020; 39:412–417. doi: 10.1016/j.healun.2020.03.008CrossrefMedlineGoogle Scholar eLetters(0)eLetters should relate to an article recently published in the journal and are not a forum for providing unpublished data. Comments are reviewed for appropriate use of tone and language. Comments are not peer-reviewed. Acceptable comments are posted to the journal website only. Comments are not published in an issue and are not indexed in PubMed. Comments should be no longer than 500 words and will only be posted online. References are limited to 10. Authors of the article cited in the comment will be invited to reply, as appropriate.Comments and feedback on AHA/ASA Scientific Statements and Guidelines should be directed to the AHA/ASA Manuscript Oversight Committee via its Correspondence page.Sign In to Submit a Response to This Article Previous Back to top Next FiguresReferencesRelatedDetailsCited By Phillips K, James L, Rabadi M, Grossi E, Smith D, Galloway A and Moazami N (2024) Impact of the coronavirus disease 2019 pandemic on drug overdoses in the United States and the effect on cardiac transplant volume and survival, The Journal of Heart and Lung Transplantation, 10.1016/j.healun.2023.10.015, 43:3, (471-484), Online publication date: 1-Mar-2024. Manla Y, Badarin F, Bader N, Lee-St John T, Mehra M and Bader F (2023) Worldwide and Country-Specific Impact of the COVID-19 Pandemic on Heart Transplantation Volumes: A Longitudinal Analysis of 2020 and 2021, Current Problems in Cardiology, 10.1016/j.cpcardiol.2023.101870, 48:11, (101870), Online publication date: 1-Nov-2023. Madan S, Chan M, Saeed O, Hemmige V, Sims D, Forest S, Goldstein D, Patel S and Jorde U (2023) Early Outcomes of Adult Heart Transplantation From COVID-19 Infected Donors, Journal of the American College of Cardiology, 10.1016/j.jacc.2023.04.022, 81:24, (2344-2357), Online publication date: 1-Jun-2023. Xie M, Su J, Zhou S, Li J and Zhang K (2023) Application of Hydrogels as Three-Dimensional Bioprinting Ink for Tissue Engineering, Gels, 10.3390/gels9020088, 9:2, (88) Song J, Huang J, Hsu Y, Lo M, Lin C, Shen T, Liao M and Lu K (2023) Coronavirus disease 2019 and cardiovascular disease, Tzu Chi Medical Journal, 10.4103/tcmj.tcmj_219_22, 35:3, (213-220), . DEFILIPPIS E, ALLEN L, BHATT A, JOSEPH S, KITTLESON M, VARDENY O, DRAZNER M and LALA A (2022) Vaccines, Antibodies and Donors: Varying Attitudes and Policies Surrounding COVID-19 and Heart Transplantation, Journal of Cardiac Failure, 10.1016/j.cardfail.2022.05.009, 28:12, (1727-1732), Online publication date: 1-Dec-2022. Freundt M, Lavanga E and Brehm C (2022) Optimal, Early Postoperative Management of Cardiac Transplant and Durable Left Ventricular Assist Recipients, Current Cardiology Reports, 10.1007/s11886-022-01823-0, 24:12, (2023-2029), Online publication date: 1-Dec-2022. Ferreira J and Poltronieri N (2022) Qualidade de Vida dos Pacientes Transplantados Cardíacos Durante a Pandemia de Covid-19, Brazilian Journal of Transplantation, 10.53855/bjt.v25i3.455_pt, 25:3 Ferreira J and Poltronieri N (2022) Quality of Life of Heart Transplant Patients During the COVID-19 Pandemic, Brazilian Journal of Transplantation, 10.53855/bjt.v25i3.455_in, 25:3 Ferreira J and Poltronieri N (2022) Calidad de Vida de los Pacientes Transplantados de Corazón Durante la Pandemic de COVID-19, Brazilian Journal of Transplantation, 10.53855/bjt.v25i3.455_esp, 25:3 Gimpel D, Crouch G, Szpytma M, Mazzone A, Baker R and Bennetts J (2022) Development of an organ procurement team in South Australia in response to COVID ‐19 , ANZ Journal of Surgery, 10.1111/ans.17776, 92:7-8, (1863-1866), Online publication date: 1-Jul-2022. Martens T, Hens L, De Pauw M and Van Belleghem Y (2022) Heart Transplantation Complicated by COVID-19 Infection, The Annals of Thoracic Surgery, 10.1016/j.athoracsur.2021.07.003, 113:4, (e267-e269), Online publication date: 1-Apr-2022. Cherry A, Nelson M and Pal N (2022) Editorial: cardiovascular anaesthesiology, Current Opinion in Anaesthesiology, 10.1097/ACO.0000000000001085, 35:1, (1-4), Online publication date: 1-Feb-2022. Bhatt A, Adler E, Albert N, Anyanwu A, Bhadelia N, Cooper L, Correa A, Defilippis E, Joyce E, Sauer A, Solomon S, Vardeny O, Yancy C and Lala A (2022) Coronavirus Disease-2019 and Heart Failure: A Scientific Statement From the Heart Failure Society of America, Journal of Cardiac Failure, 10.1016/j.cardfail.2021.08.013, 28:1, (93-112), Online publication date: 1-Jan-2022. NOVYSEDLAK R, VACHTENHEIM J, STRIZ I, VIKLICKY O, LISCHKE R and STRIZOVA Z (2021) SARS-CoV-2 Viral Load Assessment in Lung Transplantation, Physiological Research, 10.33549/physiolres.934760, (S253-S258) Tchana-Sato V, Ancion A, Tridetti J, Sakalihasan N, Hayette M, Detry O, Delvenne P, Amabili P, Senard M, Hougrand O, Szecel D, Lavigne J, Minga Lowampa E, Ponte C, Maquoi I, Morimont P, Van Den Bulck M, Delbouille M, Defraigne J and Lancellotti P (2021) Clinical course and challenging management of early COVID-19 infection after heart transplantation: case report of two patients, BMC Infectious Diseases, 10.1186/s12879-021-05793-6, 21:1, Online publication date: 1-Dec-2021. Tu A and Lewis J (2021) Biomaterial-based immunotherapeutic strategies for rheumatoid arthritis, Drug Delivery and Translational Research, 10.1007/s13346-021-01038-w, 11:6, (2371-2393), Online publication date: 1-Dec-2021. Ashfaq A, Gray G, Carapellucci J, Amankwah E, Ahumada L, Rehman M, Puchalski M, Smith A, Quintessenza J and Asante-Korang A (2021) Impact of Coronavirus-2019 On Pediatric and Adult Heart Transplantation Waitlist Activity and Mortality in The United States: A Descriptive Approach, The Lancet Regional Health - Americas, 10.1016/j.lana.2021.100060, 3, (100060), Online publication date: 1-Nov-2021. Sadlonova M, Gerecke B, Herrmann-Lingen C, Kutschka I, Skott-Schmiegelow S, D'Elia E, Mandoli G, Parollo M and Sunjaya A (2021) Heart transplantation in the era of COVID-19 pandemic: delirium, post-transplant depression, and visitor restrictions; the role of liaison and inpatient psychosomatic treatment—a case report, European Heart Journal - Case Reports, 10.1093/ehjcr/ytab355, 5:10, Online publication date: 3-Oct-2021. Chouairi F, Fuery M, Clark K, Mullan C, Stewart J, Caraballo C, Clarke J, Sen S, Guha A, Ibrahim N, Cole R, Holaday L, Anwer M, Geirsson A, Rogers J, Velazquez E, Desai N, Ahmad T and Miller P (2021) Evaluation of Racial and Ethnic Disparities in Cardiac Transplantation, Journal of the American Heart Association, 10:17, Online publication date: 7-Sep-2021. Itzhaki Ben Zadok O, Shaul A, Ben‐Avraham B, Yaari V, Ben Zvi H, Shostak Y, Pertzov B, Eliakim‐Raz N, Abed G, Abuhazira M, Barac Y, Mats I, Kramer M, Aravot D, Kornowski R and Ben‐Gal T (2021) Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients – a prospective cohort study , European Journal of Heart Failure, 10.1002/ejhf.2199, 23:9, (1555-1559), Online publication date: 1-Sep-2021. Mahrokhian S, Liang C, Nordan T, Vest A, Kiernan M, DeNofrio D, Couper G and Kawabori M (2021) The Impact of COVID-19 on Heart Transplantations and Waitlist Additions in the United States, ASAIO Journal, 10.1097/MAT.0000000000001499, 67:7, (721-723), Online publication date: 1-Jul-2021. Soltesz E (2021) Commentary: From the trenches: Lessons on caring for patients with heart failure during coronavirus disease 2019 (COVID-19), The Journal of Thoracic and Cardiovascular Surgery, 10.1016/j.jtcvs.2020.09.004, 162:1, (136-137), Online publication date: 1-Jul-2021. Yuan Q, Haque O, Coe T and Markmann J (2021) The Heterogenous Effect of COVID-19 on Liver Transplantation Activity and Waitlist Mortality in the United States, Frontiers in Surgery, 10.3389/fsurg.2021.669129, 8 Awad W and Bashir M (2021) Mechanical circulatory support—Challenges, strategies, and preparations, Journal of Cardiac Surgery, 10.1111/jocs.15301, 36:5, (1723-1728), Online publication date: 1-May-2021. Hardman G, Sutcliffe R, Hogg R, Mumford L, Grocott L, Jerrett L, Mead‐Regan S, Nuttall J, Dunn S, Seeley P, Quigley R, Dalzell J, Al‐Attar N, Parameshwar J, Fisher A, Booth K and Dark J (2021) Heart transplantation in the UK during the first wave of the SARS‐CoV‐2 pandemic, Clinical Transplantation, 10.1111/ctr.14261, 35:5, Online publication date: 1-May-2021. Shi G, Huang J, Pi M, Chen X, Li X, Ding Y, Zhang H, Xiao D, Huang G, Ming T, Huang P, Liu C, Zhao Q, Tian H, Chen R, Guo J, Tang J, Chen W and Chen H (2021) Impact of early Coronavirus Disease 2019 pandemic on pediatric cardiac surgery in China, The Journal of Thoracic and Cardiovascular Surgery, 10.1016/j.jtcvs.2020.11.074, 161:5, (1605-1614.e4), Online publication date: 1-May-2021. Tong C and Khush K (2021) New Approaches to Donor Selection and Preparation in Heart Transplantation, Current Treatment Options in Cardiovascular Medicine, 10.1007/s11936-021-00906-5, 23:5, Online publication date: 1-May-2021. Bagozzi L, Bottio T, Tarzia V, D'Onofrio A, Gambino A, Bianco R, Toscano G and Gerosa G (2021) Can Patients Be Transplanted or Undergo Ventricular Assist Device Placement During the COVID-19 Pandemic? Padova Perspective, ASAIO Journal, 10.1097/MAT.0000000000001400, 67:4, (395-396), Online publication date: 1-Apr-2021. Johnstad C, Murray D, Dhingra R, Smith J and Fiedler A (2021) Successful heart transplantation in a patient who recovered from COVID‐19, Journal of Cardiac Surgery, 10.1111/jocs.15331, 36:3, (1148-1149), Online publication date: 1-Mar-2021. García-Pinilla J, García-Cosío Carmena M, Farrero-Torres M, Recio-Mayoral A and González-Costello J (2021) Selección de lo mejor del año 2020 en insuficiencia cardiaca, REC: CardioClinics, 10.1016/j.rccl.2020.11.009, 56, (66-71), Online publication date: 1-Jan-2021. Bader F, Manla Y, Atallah B and Starling R (2020) Heart failure and COVID-19, Heart Failure Reviews, 10.1007/s10741-020-10008-2, 26:1, (1-10), Online publication date: 1-Jan-2021. Afshar Z, Babazadeh A, Javanian M, Ramezani E, Shemshadi R and Ebrahimpour S (2020) A review of cardiac involvement in COVID-19 infection, Cor et Vasa, 10.33678/cor.2020.102, 62:6, (610-615), Online publication date: 11-Dec-2020. Cravedi P, Schold J, Safa K, Kates O, Elfadawy N, Mannon R, Shah M, Hammond S, Avery R, Guerrero Miranda C, Riella L, Jowsey‐Gregoire S, Akalin E, Camirand G, Alegre M and Azzi J (2020) The COVID‐19 pandemic: A community approach, Clinical Transplantation, 10.1111/ctr.14059, 34:11, Online publication date: 1-Nov-2020. Bittencourt M, Generoso G, Melo P, Peixoto D, Miranda É, Mesquita E, Brandão A, Saraiva J, Barberato S, Bacal F and Lopes M (2020)(2020)(2020)(2020) Posicionamento – Protocolo de Reconexão dos Serviços de Cardiologia com os Pacientes Durante a Pandemia de COVID-19 – 2020, Arquivos Brasileiros de Cardiologia, 10.36660/abc.20201004, 115:4, (776-799), Online publication date: 13-Oct-2020., Online publication date: 13-Oct-2020., Online publication date: 1-Oct-2020., Online publication date: 1-Oct-2020. Chatzis D, Magounaki K, Pantazopoulos I, Johnson E and Tsioufis K COVID-19 pandemic and cardiovascular disease: where do we stand?, Minerva Cardioangiologica, 10.23736/S0026-4725.20.05298-6, 68:4 Lima B, Gibson G, Vullaganti S, Malhame K, Maybaum S, Hussain S, Shah S, Majure D, Wallach F, Jang K, Bijol V, Esposito M, Williamson A, Thomas R, Bhuiya T, Fernandez H and Stevens G (2020) COVID‐19 in recent heart transplant recipients: Clinicopathologic features and early outcomes, Transplant Infectious Disease, 10.1111/tid.13382, 22:5, Online publication date: 1-Oct-2020. DeFilippis E, Reza N, Donald E, Givertz M, Lindenfeld J and Jessup M (2020) Considerations for Heart Failure Care During the COVID-19 Pandemic, JACC: Heart Failure, 10.1016/j.jchf.2020.05.006, 8:8, (681-691), Online publication date: 1-Aug-2020. Ranard L, Fried J, Abdalla M, Anstey D, Givens R, Kumaraiah D, Kodali S, Takeda K, Karmpaliotis D, Rabbani L, Sayer G, Kirtane A, Leon M, Schwartz A, Uriel N and Masoumi A (2020) Approach to Acute Cardiovascular Complications in COVID-19 Infection, Circulation: Heart Failure, 13:7, Online publication date: 1-Jul-2020. Vechorko V, Gordeev I, Gubareva E, Ryndyaeva E and Averkov O (2020) COVID-19 infection after recent heart transplantation: a case report, Russian Journal of Cardiology, 10.15829/1560-4071-2020-3904, 25:5, (3904) June 23, 2020Vol 141, Issue 25 Advertisement Article InformationMetrics © 2020 American Heart Association, Inc.https://doi.org/10.1161/CIRCULATIONAHA.120.047096PMID: 32314596 Originally publishedApril 21, 2020 Keywordscoronavirusheart transplantationimmunosuppressionpandemicPDF download Advertisement SubjectsComplicationsEthics and PolicyHeart FailureTransplantation
Referência(s)